CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Rhea-AI Summary

CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company specializing in bladder cancer therapeutics, announced its participation in the Goldman Sachs 46th Annual Global Healthcare Conference. Chairman & CEO Arthur Kuan will engage in a fireside chat at the conference in Miami Beach on June 10, 2025, at 11:20 am ET. The presentation will be accessible via live audio webcast through the company's Investor Relations website, with replay available for approximately 90 days post-event. CG Oncology focuses on developing bladder-sparing therapeutic solutions for bladder cancer patients.

News Market Reaction – CGON

+0.19%

+0.19% Session move

In the trading session that priced this news, CGON gained 0.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.

Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.

About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Contacts:
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
(508) 654-2277
sarah.connors@cgoncology.com

Investor Relations
Chau Cheng
Vice President, Investor Relations, CG Oncology
(949) 342-8939
chau.cheng@cgoncology.com

FAQ

When is CG Oncology (CGON) presenting at the Goldman Sachs Healthcare Conference 2025?

CG Oncology will present at the Goldman Sachs Healthcare Conference on Tuesday, June 10, 2025, at 11:20 am ET in Miami Beach, FL.

Who will represent CG Oncology (CGON) at the Goldman Sachs Healthcare Conference?

Arthur Kuan, Chairman & Chief Executive Officer of CG Oncology, will represent the company in a fireside chat at the conference.

How can investors access CG Oncology's (CGON) presentation at the Goldman Sachs conference?

Investors can access the live audio webcast through the Investor Relations section of CG Oncology's website at www.cgoncology.com.

What is CG Oncology's (CGON) main focus in drug development?

CG Oncology is focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer.

How long will the replay of CG Oncology's (CGON) Goldman Sachs conference presentation be available?

The webcast replay will be available for approximately 90 days after the conclusion of the live presentation.